Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population

Michael Clearfield, Edwin J. Whitney, Stephen Weis, John R Downs, Deborah R. Shapiro, Evan A. Stein, Douglas J. Watson, Alexandra Langendörfer, Polly A. Beere, Jeremiah Stamler, Antonio M. Gotto

Research output: Contribution to journalArticle

Abstract

Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)125-133
Number of pages9
JournalJournal of Cardiovascular Risk
Volume7
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Coronary Artery Disease
Cholesterol
Air
Lovastatin
Cohort Studies
Placebos
HDL Cholesterol
Population
Diet Therapy
Fat-Restricted Diet
Nutrition Surveys
Primary Prevention
Hispanic Americans
LDL Cholesterol
Life Style
Triglycerides
Cardiovascular Diseases
Demography
Lipids
Therapeutics

Keywords

  • Cholesterol
  • Controlled clinical trials
  • Lovastatin
  • Primary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clearfield, M., Whitney, E. J., Weis, S., Downs, J. R., Shapiro, D. R., Stein, E. A., ... Gotto, A. M. (2000). Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population. Journal of Cardiovascular Risk, 7(2), 125-133.

Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS) : Baseline Characteristics and comparison with USA population. / Clearfield, Michael; Whitney, Edwin J.; Weis, Stephen; Downs, John R; Shapiro, Deborah R.; Stein, Evan A.; Watson, Douglas J.; Langendörfer, Alexandra; Beere, Polly A.; Stamler, Jeremiah; Gotto, Antonio M.

In: Journal of Cardiovascular Risk, Vol. 7, No. 2, 2000, p. 125-133.

Research output: Contribution to journalArticle

Clearfield, M, Whitney, EJ, Weis, S, Downs, JR, Shapiro, DR, Stein, EA, Watson, DJ, Langendörfer, A, Beere, PA, Stamler, J & Gotto, AM 2000, 'Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population', Journal of Cardiovascular Risk, vol. 7, no. 2, pp. 125-133.
Clearfield, Michael ; Whitney, Edwin J. ; Weis, Stephen ; Downs, John R ; Shapiro, Deborah R. ; Stein, Evan A. ; Watson, Douglas J. ; Langendörfer, Alexandra ; Beere, Polly A. ; Stamler, Jeremiah ; Gotto, Antonio M. / Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS) : Baseline Characteristics and comparison with USA population. In: Journal of Cardiovascular Risk. 2000 ; Vol. 7, No. 2. pp. 125-133.
@article{356fde6a9d8044ca8f7e6be5e60f9125,
title = "Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population",
abstract = "Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85{\%}) and 997 women (15{\%}) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89{\%} white, 7{\%} Hispanic, and 3{\%} black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Cholesterol, Controlled clinical trials, Lovastatin, Primary prevention",
author = "Michael Clearfield and Whitney, {Edwin J.} and Stephen Weis and Downs, {John R} and Shapiro, {Deborah R.} and Stein, {Evan A.} and Watson, {Douglas J.} and Alexandra Langend{\"o}rfer and Beere, {Polly A.} and Jeremiah Stamler and Gotto, {Antonio M.}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "125--133",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS)

T2 - Baseline Characteristics and comparison with USA population

AU - Clearfield, Michael

AU - Whitney, Edwin J.

AU - Weis, Stephen

AU - Downs, John R

AU - Shapiro, Deborah R.

AU - Stein, Evan A.

AU - Watson, Douglas J.

AU - Langendörfer, Alexandra

AU - Beere, Polly A.

AU - Stamler, Jeremiah

AU - Gotto, Antonio M.

PY - 2000

Y1 - 2000

N2 - Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

AB - Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

KW - Cholesterol

KW - Controlled clinical trials

KW - Lovastatin

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=0034123613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034123613&partnerID=8YFLogxK

M3 - Article

C2 - 10879416

VL - 7

SP - 125

EP - 133

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 2

ER -